Tissuemed is delighted to announce it has been successfully shortlisted for an Outstanding Achievement Award at this year’s prestigious Medilink Healthcare Business Awards, taking place next month in Sheffield.
The nomination, judged by an independent panel of experts recognises Tissuemed’s achievement in obtaining Chinese regulatory approval (CFDA) for the TissuePatch™ Product Range. The Chinese market for medical devices is growing rapidly, driven by an increase in healthcare spending in what is the world’s most populous country.
For Tissuemed, David Mandley, CEO commented, “TissuePatch™ is the first and only synthetic sealantto be approved by the Chinese FDA, giving us sole access to this rapidly increasing medical device market. We have achieved a broad indication for use, which adds up to even more potential for the company. With regulatory requirements in China becoming ever more challenging this approval is testament to Tissuemed’s proven technology, our robust Quality System and the hard work of our colleagues.”
David added, “We look forward to joining the Medilink family in Sheffield on the 2nd March and celebrating achievements in the Healthcare Industry over the last 12 months.”